A post to the clinicaltrials.gov website last updated on December 5 states that sponsor Gilead Sciences terminated a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583 in participants with advanced solid tumors. The study, which was intended to characterize the safety and tolerability of GS-3583 as monotherapy, and to determine the maximum tolerated dose or recommended Phase 2 dose of GS-3583 as monotherapy in participants with advanced solid tumors, was terminated due to a "sponsor decision to prematurely discontinue the study, following an internal safety assessment of the molecule," according to the post. Reference Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead price target raised to $105 from $95 at Oppenheimer
- Biotech Alert: Searches spiking for these stocks today
- EC authorizes new low-dose of Gilead’s Biktarvy to treat HIV in children
- Gilead management to meet virtually with Oppenheimer
- Gilead, Arcus provide update from fourth interim analysis of ARC-7 study